Recent Progress in Clinical Application of Ranibizumab
- VernacularTitle:雷珠单抗临床应用新进展概述
- Author:
Jing GAO
;
Difeng LIU
;
Lin CAI
- Publication Type:Journal Article
- Keywords:
Ranibizumab;
VEGF suppressant;
Clinical application;
Progress
- From:
China Pharmacist
2015;(3):479-482
- CountryChina
- Language:Chinese
-
Abstract:
Ranibizumab is a recombinant rat monoclonal antibody fragment of the second generation humanized VEGF. Ranibi-zumab can bind all of active VEGF-A to inhibit the bond between VEGF-A and VEGFR1 or VEGFR2. As the results, the vascular en-dothelial proliferation and vascular permeability can be reduced, and the new vessels angiogenesis can be prevented. The article sys-tematically searched and summarized the relative literatures to offer high-quality evidences for the recent clinical application of ranibi-zumab in ophthalmology.
